trending Market Intelligence /marketintelligence/en/news-insights/trending/qdJ3_Dov9qYiOBl4j1Baew2 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

Merck, Pfizer's diabetes treatment meets primary endpoint in 2 phase 3 trials

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry


IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

Merck, Pfizer's diabetes treatment meets primary endpoint in 2 phase 3 trials

Merck & Co. Inc. and Pfizer Inc.'s oral investigational drug ertugliflozin met its primary endpoint of improving glycemic control in adults with type 2 diabetes.

Ertugliflozin belongs to a new class of diabetes medicines called SGLT-2 inhibitors and it was being investigated in separate phase 3 studies in combination with metformin or januvia.

Metformin is a standard type 2 diabetes drug sold under different brand names, including Fortamet and Glucophage, while Merck's januvia is indicated as an adjunct to diet and exercise to control type 2 diabetes.

The first study demonstrated that patients treated with ertugliflozin and metformin achieved a statistically significant reduction in blood sugar levels compared to a combination of placebo and metformin.

The second study showed that initial combination therapy of ertugliflozin and januvia led to greater reductions in average blood sugar level when compared to placebo alone.

The studies also showed significant reductions in fasting plasma glucose, body weight and systolic blood pressure — the same benefits showed by other SGLT-2 inhibitors such as AstraZeneca PLC's Farxiga, Johnson & Johnson's Invokana and Eli Lilly & Co. and Boehringer Ingelheim Corp.'s Jardiance.

Ertugliflozin continues to be studied in additional phase 3 trials.